| Citation: |
ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
|
Primary cutaneous lymphomas are a group of non-Hodgkin's lymphomas originating from the skin, with unique clinical and histological features. In December 2023, the National Comprehensive Cancer Network (NCCN) updated and released the Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1. 2024). Compared to the 2023 edition of the Guidelines, this update mainly focuses on the principles of diagnostic assessment, staging criteria, treatment principles for mycosis fungoides(MF) at different stages, and recommendations for radiotherapy. In conjunction with the current situation and characteristics of the diagnosis and treatment of primary cutaneous lymphoma in our country, this article interprets the main recommendations of the Guidelines to promote the application of clinical practices in our country.
| [1] |
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas[J]. Blood, 2019, 133(16): 1703-1714. DOI: 10.1182/blood-2018-11-881268
|
| [2] |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas(Version 1.2024)[DB/OL]. [2024-08-01]. http://www.nccn.org.
|
| [3] |
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022, 36(7): 1720-1748. DOI: 10.1038/s41375-022-01620-2
|
| [4] |
Olsen E A, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC[J]. Blood, 2022, 140(5): 419-437. DOI: 10.1182/blood.2021012057
|
| [5] |
Scarisbrick J J, Prince H M, Vermeer M H, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model[J]. J Clin Oncol, 2015, 33(32): 3766-3773. DOI: 10.1200/JCO.2015.61.7142
|
| [6] |
Olsen E A, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium[J]. J Am Acad Dermatol, 2016, 74(1): 27-58. DOI: 10.1016/j.jaad.2015.09.033
|
| [7] |
Lessin S R, Duvic M, Guitart J, et al. Topical chemother-apy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides[J]. JAMA Dermatol, 2013, 149(1): 25-32. DOI: 10.1001/2013.jamadermatol.541
|
| [8] |
Zackheim H S. Topical carmustine (BCNU) for patch/plaque mycosis fungoides[J]. Semin Dermatol, 1994, 13(3): 202-206.
|
| [9] |
Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma[J]. Arch Dermatol, 2002, 138(3): 325-332.
|
| [10] |
Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome-update 2017[J]. Eur J Cancer, 2017, 77: 57-74. DOI: 10.1016/j.ejca.2017.02.027
|
| [11] |
Duvic M, Martin A G, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma[J]. Arch Dermatol, 2001, 137(5): 581-593.
|
| [12] |
Duvic M, Tetzlaff M T, Gangar P, et al. Results of a phase Ⅱ trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis[J]. J Clin Oncol, 2015, 33(32): 3759-3765. DOI: 10.1200/JCO.2014.60.3787
|
| [13] |
Kim Y H, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(9): 1192-1204. DOI: 10.1016/S1470-2045(18)30379-6
|
| [14] |
Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome[J]. Blood, 2003, 101(11): 4267-4272. DOI: 10.1182/blood-2002-09-2802
|
| [15] |
Khodadoust M S, Rook A H, Porcu P, et al. Pembrolizu-mab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase Ⅱ study[J]. J Clin Oncol, 2020, 38(1): 20-28. DOI: 10.1200/JCO.19.01056
|
| [16] |
Million L, Yi E J, Wu F, et al. Radiation therapy for primary cutaneous anaplastic large cell lymphoma: an international lymphoma radiation oncology group multi-institutional experience[J]. Int J Radiat Oncol Biol Phys, 2016, 95(5): 1454-1459. DOI: 10.1016/j.ijrobp.2016.03.023
|
| [17] |
Fernández-de-Misa R, Hernández-Machín B, Servitje O, et al. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study[J]. Clin Exp Dermatol, 2018, 43(2): 137-143. DOI: 10.1111/ced.13256
|
| [18] |
Lewis D J, Talpur R, Huen A O, et al. Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of phase 2 results[J]. JAMA Dermatol, 2017, 153(12): 1302-1306. DOI: 10.1001/jamadermatol.2017.3593
|
| [19] |
Smith B D, Glusac E J, McNiff J M, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems[J]. J Clin Oncol, 2004, 22(4): 634-639. DOI: 10.1200/JCO.2004.08.044
|
| [20] |
Neelis K J, Schimmel E C, Vermeer M H, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas[J]. Int J Radiat Oncol Biol Phys, 2009, 74(1): 154-158. DOI: 10.1016/j.ijrobp.2008.06.1918
|
| [21] |
Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France[J]. JAMA Dermatol, 2014, 150(5): 535-541. DOI: 10.1001/jamadermatol.2013.7452
|
| [1] | JIANG Nan, TIAN Xinping, ZENG Xiaofeng. Interpretation on the 2024 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 28-34. DOI: 10.12290/xhyxzz.2024-1018 |
| [2] | JIN Shangyi, TIAN Xinping. Interpretation on the Chinese Guideline for the Diagnosis and Treatment of Takayasu's Arteritis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 560-566. DOI: 10.12290/xhyxzz.2024-0209 |
| [3] | LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043 |
| [4] | JIA Zhimeng, Rebecca Colman, NING Xiaohong. Interpretation on Management of Dyspnea in Advanced Cancer: ASCO Guideline[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 52-57. DOI: 10.12290/xhyxzz.2023-0517 |
| [5] | ZUO Wei, LIU Rongji, SUN Yajia, ZHANG Bo, CHEN Yaolong, ZHANG Shuyang. Interpretation on Management Guideline for the Off-label Use of Drugs in China(2021 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 86-93. DOI: 10.12290/xhyxzz.2022-0588 |
| [6] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
| [7] | ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805 |
| [8] | ZHAO Weigang. Interpretation on Clinical Guidelines for Prevention and Treatment of Type 2 Diabetes Mellitus in the Elderly in China (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 574-580. DOI: 10.12290/xhyxzz.2022-0199 |
| [9] | LIU Jie, LUO Yi-xin, LIU Zhao-rui, LIU Yue-hua, ZHANG Wei, LU Zhao-hui. WHO-EORTC Classification of Primary Cutaneous Lymphomas:Updates and Interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 698-702. DOI: 10.3969/j.issn.1674-9081.2020.06.011 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: